Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy - PubMed (original) (raw)
. 2008 Apr 15;46(8):1271-81.
doi: 10.1086/533468.
Wolfgang Stöhr, A Sarah Walker, Ian G Williams, Cissy Kityo, Peter Hughes, Andrew Kambugu, Charles F Gilks, Peter Mugyenyi, Paula Munderi, James Hakim, Diana M Gibb; Development of Antiretroviral Therapy Trial
Affiliations
- PMID: 18444867
- DOI: 10.1086/533468
Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy
Andrew Reid et al. Clin Infect Dis. 2008.
Abstract
Background: We sought to investigate renal function in previously untreated symptomatic human immunodeficiency virus (HIV)-infected adults with CD4(+) cell counts of <200 cells/mm(3) who were undergoing antiretroviral therapy (ART) in Africa.
Methods: The study was an observational analysis within a randomized trial of ART management strategies that included 3316 participants with baseline serum creatinine levels of < or =360 micromol/L. Creatinine levels were measured before ART initiation, at weeks 4 and 12 of therapy, and every 12 weeks thereafter. We calculated estimated glomerular filtration rate (eGFR) using the Cockcroft-Gault formula. We analyzed the incidence of severely decreased eGFR (<30 mL/min/1.73 m(2)) and changes in eGFR to 96 weeks, considering demographic data, type of ART, and baseline biochemical and hematological characteristics as predictors, using random-effects models.
Results: Sixty-five percent of the participants were women. Median values at baseline were as follows: age, 37 years; weight, 57 kg; CD4(+) cell count, 86 cells/mm(3); and eGFR, 89 mL/min/1.73 m(2). Of the participants, 1492 (45%) had mild (> or =60 but <90 mL/min/1.73 m(2)) and 237 (7%) had moderate (> or =30 but <60 mL/min/1.73 m(2)) impairments in eGFR. First-line ART regimens included zidovudine-lamivudine plus tenofovir disoproxil fumarate (for 74% of patients), nevirapine (16%), and abacavir (9%) (mostly nonrandomized allocation). After ART initiation, the median eGFR was 89-91 mL/min/1.73 m(2) for the period from week 4 through week 96. Fifty-two participants (1.6%) developed severe reductions in eGFR by week 96; there was no statistically significant difference between these patients and others with respect to first-line ART regimen received (P = .94). Lower baseline eGFR or hemoglobin level, lower body mass index, younger age, higher baseline CD4(+) cell count, and female sex were associated with greater increases in eGFR over baseline, with small but statistically significant differences between regimens (P < .001 for all).
Conclusions: Despite screening, mild-to-moderate baseline renal impairment was relatively common, but these participants had greatest increases in eGFR after starting ART. Severe eGFR impairment was infrequent regardless of ART regimen and was generally related to intercurrent disease. Differences between ART regimens with respect to changes in eGFR through 96 weeks were of marginal clinical relevance, but investigating longer-term nephrotoxicity remains important.
Similar articles
- Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.
Stöhr W, Reid A, Walker AS, Ssali F, Munderi P, Mambule I, Kityo C, Grosskurth H, Gilks CF, Gibb DM, Hakim J; DART Trial Team. Stöhr W, et al. Antivir Ther. 2011;16(7):1011-20. doi: 10.3851/IMP1832. Antivir Ther. 2011. PMID: 22024517 Clinical Trial. - Renal impairment in HIV-infected patients initiating tenofovir-containing antiretroviral therapy regimens in a Primary Healthcare Setting in South Africa.
Kamkuemah M, Kaplan R, Bekker LG, Little F, Myer L. Kamkuemah M, et al. Trop Med Int Health. 2015 Apr;20(4):518-26. doi: 10.1111/tmi.12446. Epub 2014 Dec 12. Trop Med Int Health. 2015. PMID: 25442109 - Renal outcomes in patients initiated on tenofovir disoproxil fumarate-based antiretroviral therapy at a community health centre in Malawi.
Chikwapulo B, Ngwira B, Sagno JB, Evans R. Chikwapulo B, et al. Int J STD AIDS. 2018 Jun;29(7):650-657. doi: 10.1177/0956462417749733. Epub 2018 Jan 16. Int J STD AIDS. 2018. PMID: 29334883 - Renal manifestations of HIV during the antiretroviral era in South Africa: a systematic scoping review.
Assaram S, Magula NP, Mewa Kinoo S, Mashamba-Thompson TP. Assaram S, et al. Syst Rev. 2017 Oct 13;6(1):200. doi: 10.1186/s13643-017-0605-5. Syst Rev. 2017. PMID: 29029647 Free PMC article. Review. - Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
Sturt AS, Dokubo EK, Sint TT. Sturt AS, et al. Cochrane Database Syst Rev. 2010 Mar 17;(3):CD008440. doi: 10.1002/14651858.CD008440. Cochrane Database Syst Rev. 2010. PMID: 20238370 Review.
Cited by
- Prevalence and predictors of long-term progression of chronic kidney disease in people with HIV in Ghana from 2003-2018.
Chadwick DR, Barker F, Smith C, Perditer O, Hardy Y, Owusu D, Villa G, Sarfo FS, Geretti AM, Phillips R. Chadwick DR, et al. BMC Nephrol. 2024 Jul 29;25(1):241. doi: 10.1186/s12882-024-03537-7. BMC Nephrol. 2024. PMID: 39075393 Free PMC article. - Increased Systemic Immune-Inflammation Index Was Associated with Type 2 Diabetic Peripheral Neuropathy: A Cross-Sectional Study in the Chinese Population.
Li J, Zhang X, Zhang Y, Dan X, Wu X, Yang Y, Chen X, Li S, Xu Y, Wan Q, Yan P. Li J, et al. J Inflamm Res. 2023 Dec 11;16:6039-6053. doi: 10.2147/JIR.S433843. eCollection 2023. J Inflamm Res. 2023. PMID: 38107379 Free PMC article. - Factors Associated with Antiretroviral Therapy Toxicity Out-Comes in Patients with and without Hypertension.
Dlamini SB, Wu MT, Dahms HU. Dlamini SB, et al. Int J Environ Res Public Health. 2022 Sep 3;19(17):11051. doi: 10.3390/ijerph191711051. Int J Environ Res Public Health. 2022. PMID: 36078765 Free PMC article. - Kidney function in tenofovir disoproxil fumarate-based oral pre-exposure prophylaxis users: a systematic review and meta-analysis of published literature and a multi-country meta-analysis of individual participant data.
Schaefer R, Amparo da Costa Leite PH, Silva R, Abdool Karim Q, Akolo C, Cáceres CF, Dourado I, Green K, Hettema A, Hoornenborg E, Jana S, Kerschberger B, Mahler H, Matse S, McManus H, Molina JM, Reza-Paul S, Azwa I, Shahmanesh M, Taylor D, Vega-Ramirez H, Veloso VG, Baggaley R, Dalal S. Schaefer R, et al. Lancet HIV. 2022 Apr;9(4):e242-e253. doi: 10.1016/S2352-3018(22)00004-2. Epub 2022 Mar 7. Lancet HIV. 2022. PMID: 35271825 Free PMC article. - APOL1 Renal Risk Variants and Kidney Function in HIV-1-Infected People From Sub-Saharan Africa.
Kabore NF, Cournil A, Poda A, Ciaffi L, Binns-Roemer E, David V, Eymard-Duvernay S, Zoungrana J, Semde A, Sawadogo AB, Koulla-Shiro S, Kouanfack C, Ngom-Gueye NF, Meda N, Winkler C, Limou S. Kabore NF, et al. Kidney Int Rep. 2021 Oct 16;7(3):483-493. doi: 10.1016/j.ekir.2021.10.009. eCollection 2022 Mar. Kidney Int Rep. 2021. PMID: 35257061 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- G0600344/MRC_/Medical Research Council/United Kingdom
- MC_U122886352/MRC_/Medical Research Council/United Kingdom
- MC_U950080931/MRC_/Medical Research Council/United Kingdom
- G0000068/MRC_/Medical Research Council/United Kingdom
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous